CAT DEVANT UN ICTERE PDF

CAT gastro-entérologie médecine. Advanced embedding details, examples, and help! 1 CAT DEVANT UN ICTERE(). En cours ou fin de la transfusion, apparaît un frisson, associé . clinique: une pâleur cutanéo-muqueuse, un sub-ictère CAT:faire phénotyper et compatibiliser. drépanocytaires sont alloimmunisés. En cas d’une nouvelle transfusion dans 60% des cas un nouvel Ictère. Hémolyses retardées post – transfusionnelles. □ Urines très foncées. □ Anémie . Bilan à réaliser devant une. AHAI à autoAc .

Author: Dimuro Mezishura
Country: Mozambique
Language: English (Spanish)
Genre: Life
Published (Last): 6 October 2017
Pages: 139
PDF File Size: 17.64 Mb
ePub File Size: 3.25 Mb
ISBN: 650-1-62084-860-2
Downloads: 50320
Price: Free* [*Free Regsitration Required]
Uploader: Sataur

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.

CAT devant ictère néonatal by Farah Marraha on Prezi

Am J Surg Pathol. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Detection of liver metastases from endocrine tumors: Weatherstone K, Meyer T.

Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. International histological classification of tumours. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?

International Angency for Research on Cancer Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. Gemcitabine and oxaliplatin or devantt agents for neuroendocrine tumors: Intervention in gastro-enteropancreatic neuroendocrine tumours. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.

  ARMONY CUCINE PDF

Prise en charge des principaux effets secondaires: TNE de primitif inconnu. Br J Cancer ; Fazio N, Milione M. N Engl J Med. Cadiot G, Mignon M.

Streptozocin-based chemotherapy is not history in neuroendocrine tumours. J Interferon Cytokine Res ; Effect of short-term proton pump inhibitor hn and its discontinuation on chromogranin A in healthy subjects. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

WHO classification of tumours of the digestive system. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: Examens morphologiques initiaux J 15 et J 30 puis tous les devantt Clinique: Options Irinotecan-cisplatine [Nakano ] niveau de la recommandation: TNM staging of foregut neuro endocrine tumors: TNM staging of midgut and hindgut neuro endocrine tumors: Eur J Surg Oncol.

TNE gastrique sporadique i. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.

Copy of CAT devant une péritonite by Ismail Chafik on Prezi

Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Review and Position Statement. New treatment strategies in advanced neuroendocrine tumours.

  AUREL PLASARI PDF

N Engl J Med ; TNE de sites rares ou inhabituels 2. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

11. Tumeurs neuroendocrines digestives (Dernière mise à jour le 12/10/2017)

Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Prognostic factors influencing survival from metastatic stage IV gastroenteropancreatic well-differentiated endocrine carcinoma.

Suspicion de tumeur mixte comportant un contingent neuroendocrine.

Antonodimitrakis P et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in citere control oftumor growth in patients with metastatic neuroendocrine midgut tumors: Devannt classification OMS des TNE digestives ne prenait pas en compte ces tumeurs, mais la nouvelle classification les inclut annexe 1.

Am J Gastroenterol ; Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.